Prognosis
Gilead Chooses Middle Ground in Pricing of Its Coronavirus Drug
- Drugmaker to charge $520 per vial for U.S. commercial insurers
- Governments can purchase drug directly at lower cost
This article is for subscribers only.
Gilead Sciences Inc. said that it will charge U.S. hospitals roughly $3,120 for most patients who need remdesivir, picking a middle ground in a high-profile decision on the cost of one of the first drugs for Covid-19.
Patients suffering from the illness caused by the novel coronavirus are usually given six vials of remdesivir over five days. The price, which comes to $520 a vial, would apply to commercially insured patients in the U.S., according to a letter from Gilead Chief Executive Officer Daniel O’Day posted on the company’s website Monday.